ProfileGDS5678 / 1432350_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 28% 28% 23% 28% 33% 52% 53% 28% 27% 29% 38% 34% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6682328
GSM967853U87-EV human glioblastoma xenograft - Control 22.6443728
GSM967854U87-EV human glioblastoma xenograft - Control 32.5477523
GSM967855U87-EV human glioblastoma xenograft - Control 42.5904328
GSM967856U87-EV human glioblastoma xenograft - Control 52.7085433
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3511352
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3932153
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6322628
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5858527
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6456129
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8612338
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7503834
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6203127
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6210527